Daniella Rylander

2010 Lund University, Lund, Skåne län, Sweden 
"Daniella Rylander"
Mean distance: 17.2 (cluster 11)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Pereira M, Pfisterer U, Rylander D, et al. (2014) Highly efficient generation of induced neurons from human fibroblasts that survive transplantation into the adult rat brain. Scientific Reports. 4: 6330
Rylander D, Bagetta V, Pendolino V, et al. (2013) Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. Proceedings of the National Academy of Sciences of the United States of America. 110: E4375-84
Rylander D. (2013) Restoration of synaptic plasticity in the host striatum: can transplants make it? Neuroreport. 24: 1016-8
Iderberg H, Rylander D, Bimpisidis Z, et al. (2013) Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Experimental Neurology. 250: 116-24
Rylander D, Lindgren HS. (2013) The serotonergic component in Parkinson's disease symptoms and therapy side-effects Serotonergic Systems: Evolution, Functions and Roles in Disease. 107-129
Rylander D. (2012) The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery. Parkinsonism & Related Disorders. 18: S126-8
Lindgren HS, Rylander D, Iderberg H, et al. (2011) Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. Journal of Parkinson's Disease. 1: 347-57
Rylander D, Parent M, O'Sullivan SS, et al. (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Annals of Neurology. 68: 619-28
Malmlöf T, Rylander D, Alken RG, et al. (2010) Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. Experimental Neurology. 225: 408-15
Rylander D, Iderberg H, Li Q, et al. (2010) A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiology of Disease. 39: 352-61
See more...